Daily Bulletin

Men's Weekly

.

Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
  • Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patients
  • PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs. 8.19% in the ESR1 mutation population
  • Data demonstrated elacestrant significantly reduced the risk of...

Read more: Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD...

Business News

Tips for Avoiding Probate Delays

Probate can be a lengthy process at the best of times, and delays often compound the stress that comes with managing a loved one's estate. Many of those delays are avoidable with the right preparati...

Daily Bulletin - avatar Daily Bulletin

Integrating Marketing Automation Workflows with Headless CMS: Creating a Unified Engine for Scalable Growth

Marketing automation is a necessary component of modern engagement with customers. Automated emails, triggered campaigns, lead nurturing and lifecycle messaging enable brands to scale their messagin...

Daily Bulletin - avatar Daily Bulletin

Why Split Corrugated Conduits Are Essential For Protecting Electrical And Solar Installations

Modern electrical systems require reliable protection for wiring and cables to ensure safety, durability, and long-term performance. In residential, commercial, and industrial environments, conduits a...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business